What is the recommended treatment protocol for an older adult with mild to moderate Alzheimer's disease using donepezil (Aricept)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Donepezil Treatment Protocol for Mild to Moderate Alzheimer's Disease

Start donepezil at 5 mg once daily in the evening before bedtime, then increase to 10 mg daily after 4-6 weeks if well tolerated. 1, 2

Initial Dosing Strategy

  • Begin with 5 mg once daily taken in the evening, just prior to retiring 1, 2
  • Maintain this starting dose for a minimum of 4-6 weeks before considering dose escalation 1, 2
  • Taking donepezil at bedtime rather than in the morning reduces sleep disturbances 1
  • The 70-hour half-life supports once-daily dosing 1

Dose Escalation

  • Increase to 10 mg once daily after 4-6 weeks if the patient tolerates the initial dose well 1, 2
  • The 10 mg dose provides superior cognitive and functional benefits compared to 5 mg, though the difference is modest 1, 3
  • While 10 mg did not achieve statistically significantly greater clinical benefit than 5 mg in all studies, dose trend analyses suggest some patients derive additional benefit from the higher dose 3
  • Do not escalate to 23 mg daily—this higher dose shows no greater efficacy than 10 mg but causes significantly more adverse events and withdrawals 4

Expected Benefits and Timeline

  • Cognitive improvements appear as early as 3 weeks but require 6-12 months to properly assess the full therapeutic response 2, 5
  • Donepezil produces statistically significant improvements in cognition (ADAS-Cog) and global function (CIBIC-plus), though the average improvement does not reach the 4-point ADAS-Cog threshold considered clinically significant 6, 1
  • Benefits are maintained for approximately 21-81 weeks with the 10 mg dose 1, 5
  • A subset of patients will achieve clinically meaningful improvement even though average improvements are modest 6, 1
  • All patients continue to decline over time despite treatment—donepezil slows but does not stop disease progression 2

Managing Side Effects

  • The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and anorexia 6, 7
  • These effects are dose-related, with the 10 mg dose carrying 2.5-3.2 times higher risk than 5 mg 1
  • Minimize side effects by taking donepezil with food and using gradual dose titration over 4-6 weeks rather than rapid escalation 1, 7
  • Most cholinergic side effects are mild, transient, and typically subside after a few weeks 6, 7
  • Unlike tacrine, donepezil does not cause hepatotoxicity and does not require liver function monitoring 6, 7, 5

Contraindications and Precautions

  • Major contraindications include uncontrolled asthma, angle-closure glaucoma, sick sinus syndrome, and left bundle-branch block 2
  • Do not prescribe donepezil for mild cognitive impairment—evidence shows no significant benefit in this population 6, 1
  • Monitor for bradycardia, though clinically significant ECG changes are uncommon 8
  • Be aware of potential drug interactions with strong CYP3A4 inhibitors (ketoconazole increases donepezil levels by 36%) and CYP2D6 inhibitors (increase donepezil levels by 17-23%) 3

Alternative Cholinesterase Inhibitors

If donepezil is not tolerated or proves ineffective:

  • Switch to rivastigmine: start 1.5 mg twice daily with food, increase by 1.5 mg twice daily every 4 weeks as tolerated to maximum 6 mg twice daily 6, 2
  • Switch to galantamine: start 4 mg twice daily with meals, increase to 8 mg twice daily after 4 weeks, with possible further increase to 12 mg twice daily based on benefit and tolerability 6, 2
  • Tacrine is no longer considered first-line treatment due to hepatotoxicity requiring biweekly liver monitoring for 16 weeks 6

Discontinuation Criteria

Stop donepezil if:

  • Side effects develop and do not resolve despite management strategies 2
  • Poor medication adherence occurs 2
  • Continued deterioration at the pre-treatment rate persists after 6-12 months of therapy 2
  • Disease progresses to severe or end-stage dementia 2

Essential Non-Pharmacologic Interventions

Implement these strategies alongside medication:

  • Establish predictable daily routines for exercise, meals, and bedtime 6, 2
  • Simplify all tasks by breaking complex activities into steps with instructions for each 6, 2
  • Use calendars, clocks, color-coded labels, and graphic cues for orientation 6
  • Ensure optimal treatment of comorbid conditions 6, 2
  • Install safety features: grab bars, safety locks on doors/gates, remove hazards like throw rugs 6
  • Control vascular risk factors and modify lifestyle (smoking cessation, regular exercise, healthy diet) 2

References

Guideline

Donepezil Dosing and Efficacy for Dementia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Mild Alzheimer's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Donepezil for dementia due to Alzheimer's disease.

The Cochrane database of systematic reviews, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.